Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MRKR Marker Therapeutics	$1.55 +28.1%	$1.16	$0.95 ▼ $5.99	$17.54M	1.29	72,380 shs	2.01 million shs
ONCR Oncorus	$0.13	$0.07	$0.01 ▼ $0.47	$3.29M	3.6	1.33 million shs	135,947 shs
SYBX Synlogic	$1.17 +1.7%	$1.12	$0.90 ▼ $1.88	$13.45M	0.56	18,185 shs	325 shs
UBX Unity Biotechnology	$0.68	$0.92	$0.66 ▼ $3.10	$11.70M	1.28	129,545 shs	178,891 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MRKR Marker Therapeutics	0.00%	+35.98%	+24.02%	+6.91%	-59.94%
ONCR Oncorus	0.00%	0.00%	0.00%	0.00%	0.00%
SYBX Synlogic	0.00%	+3.54%	+0.86%	-12.69%	-25.00%
UBX Unity Biotechnology	0.00%	-12.71%	-39.29%	-56.13%	-56.13%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MRKR Marker Therapeutics	4.1837 of 5 stars	3.8	3.0	0.0	3.9	3.3	0.8	0.6
ONCR Oncorus	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SYBX Synlogic	1.7902 of 5 stars	0.0	5.0	0.0	0.0	2.2	1.7	1.3
UBX Unity Biotechnology	4.3039 of 5 stars	3.3	4.0	0.0	4.7	2.6	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MRKR Marker Therapeutics	3.50	Strong Buy	$13.17	749.35% Upside
ONCR Oncorus	0.00	N/A	N/A	N/A
SYBX Synlogic	0.00	N/A	N/A	N/A
UBX Unity Biotechnology	2.50	Moderate Buy	$3.75	451.47% Upside

Current Analyst Ratings Breakdown

Latest ONCR, SYBX, MRKR, and UBX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	UBX Unity Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$4.00 ➝ $2.00
5/16/2025	UBX Unity Biotechnology	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$6.00 ➝ $1.00
4/23/2025	UBX Unity Biotechnology	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/23/2025	UBX Unity Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/1/2025	MRKR Marker Therapeutics	WBB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy	$12.50 ➝ $12.50
3/25/2025	UBX Unity Biotechnology	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $4.00
3/24/2025	UBX Unity Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $4.00
3/10/2025	UBX Unity Biotechnology	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
3/10/2025	UBX Unity Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
3/5/2025	MRKR Marker Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00

(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MRKR Marker Therapeutics	$6.59M	2.66	N/A	N/A	$1.58 per share	0.98
ONCR Oncorus	N/A	N/A	N/A	N/A	$2.33 per share	N/A
SYBX Synlogic	$8K	1,710.54	N/A	N/A	$4.64 per share	0.25
UBX Unity Biotechnology	$240K	48.77	N/A	N/A	$1.69 per share	0.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MRKR Marker Therapeutics	-$8.24M	-$1.33	N/A	N/A	N/A	-179.74%	-89.63%	-71.62%	8/13/2025 (Estimated)
ONCR Oncorus	-$77.42M	-$3.49	N/A	∞	N/A	N/A	N/A	N/A	N/A
SYBX Synlogic	-$57.28M	-$2.51	N/A	N/A	N/A	N/A	-207.84%	-114.81%	6/3/2025 (Estimated)
UBX Unity Biotechnology	-$39.86M	-$1.62	N/A	N/A	N/A	N/A	-119.70%	-45.86%	7/22/2025 (Estimated)

Latest ONCR, SYBX, MRKR, and UBX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/3/2025	Q1 2025	SYBX Synlogic	-$0.15	$0.0256	+$0.1756	N/A	N/A	N/A
4/22/2025	Q1 2025	UBX Unity Biotechnology	-$0.43	-$0.43	N/A	-$0.43	N/A	N/A
3/31/2025	Q4 2024	MRKR Marker Therapeutics	-$0.28	-$0.42	-$0.14	-$0.42	$5.25 million	$1.22 million
3/6/2025	Q4 2024	SYBX Synlogic	-$0.10	-$0.06	+$0.04	-$0.06	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A	N/A
ONCR Oncorus	N/A	N/A	N/A	N/A	N/A
SYBX Synlogic	N/A	N/A	N/A	N/A	N/A
UBX Unity Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MRKR Marker Therapeutics	N/A	3.15	3.15
ONCR Oncorus	N/A	N/A	N/A
SYBX Synlogic	N/A	2.71	2.71
UBX Unity Biotechnology	N/A	3.45	3.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MRKR Marker Therapeutics	22.39%
ONCR Oncorus	20.07%
SYBX Synlogic	63.40%
UBX Unity Biotechnology	29.49%

Insider Ownership

Company	Insider Ownership
MRKR Marker Therapeutics	14.50%
ONCR Oncorus	17.10%
SYBX Synlogic	3.02%
UBX Unity Biotechnology	5.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MRKR Marker Therapeutics	60	11.32 million	9.16 million	Not Optionable
ONCR Oncorus	64	26.09 million	21.63 million	Optionable
SYBX Synlogic	80	11.70 million	11.34 million	Optionable
UBX Unity Biotechnology	60	17.21 million	15.87 million	Optionable

ONCR, SYBX, MRKR, and UBX Headlines

Recent News About These Companies

HC Wainwright Issues Positive Estimate for UBX Earnings

May 30 at 1:18 AM | americanbankingnews.com

Unity Biotechnology (NASDAQ:UBX) Earns Neutral Rating from HC Wainwright

May 29, 2025 | americanbankingnews.com

HC Wainwright & Co. Downgrades Unity Biotechnology (UBX)

May 28, 2025 | msn.com

Unity Biotechnology (UBX) was downgraded to a Hold Rating at Mizuho Securities

May 18, 2025 | theglobeandmail.com

Bay Area biotech company Unity lays off every single worker, including CEO

May 7, 2025 | msn.com

Bay Area biotech company Unity, once worth $700M, lays off entire remaining workforce

May 5, 2025 | msn.com

South San Francisco biotech company lays off entire workforce, including CEO

May 5, 2025 | msn.com

Unity disbands workforce as it searches for strategic path forward, while Mammoth cuts 24 roles

May 5, 2025 | fiercebiotech.com

UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting

May 1, 2025 | globenewswire.com

NEJM Evidence publishes results from Phase 2 BEHOLD study of UBX1325

April 25, 2025 | ophthalmologytimes.com

UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates

April 22, 2025 | globenewswire.com

Unity Biotechnology price target lowered to $4 from $8 at H.C. Wainwright

March 26, 2025 | markets.businessinsider.com

Unity Biotechnology price target lowered to $4 from $6 at Chardan

March 26, 2025 | markets.businessinsider.com

Unity Biotechnology announces results from ASPIRE Phase 2b study in DME

March 25, 2025 | markets.businessinsider.com

Unity reports topline outcomes from trial of diabetic macular oedema therapy

March 25, 2025 | msn.com

UNITY Biotechnology tanks on mixed results for eye disease drug

March 25, 2025 | thepharmaletter.com

UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study

March 25, 2025 | zacks.com

UNITY Biotechnology Shares Drop 33% After Phase 2b Trial Data on UBX1325 in Diabetic Macular Edema

March 24, 2025 | finance.yahoo.com

Unity Biotechnology releases topline results from phase 2b ASPIRE trial of UBX1325 in patients with diabetic macular edema

March 24, 2025 | ophthalmologytimes.com

UNITY Biotechnology tanks after failing to meet goal in eye disorder treatment trial

March 24, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCR, SYBX, MRKR, and UBX Company Descriptions

Marker Therapeutics NASDAQ:MRKR

$1.55 +0.34 (+28.12%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$1.54 -0.01 (-0.92%)

As of 08:40 AM Eastern

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Oncorus NASDAQ:ONCR

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company develops ONCR-021 for the treatment of non-small cell lung cancer, renal cell carcinoma, melanoma, and anaplastic thyroid cancer; and ONCR-788 for the treatment of small cell lung cancer, neuroendocrine prostate, and other neuroendocrine cancers. Oncorus, Inc. was incorporated in 2015 and is headquartered in Andover, Massachusetts.

Synlogic NASDAQ:SYBX

$1.17 +0.02 (+1.74%)

Closing price 05/30/2025 03:57 PM Eastern

Extended Trading

$1.15 -0.02 (-1.71%)

As of 08:36 AM Eastern

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

Unity Biotechnology NASDAQ:UBX

$0.68 0.00 (0.00%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$0.71 +0.03 (+4.41%)

As of 08:20 AM Eastern

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time